Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Doroteya K. Todorieva"'
Autor:
Svetla O. Blazheva, K Kovacheva, Tzvetan H. Lukanov, Doroteya K. Todorieva-Todorova, Nikolay T. Tzvetkov
Publikováno v:
Journal of Biomedical and Clinical Research. 14:47-52
Summary Myeloproliferative neoplasms (MPN) are clonal hematological conditions characterized by excessive production of one or more cell lines in the bone marrow. The blood cells produced are often hyperactive in their functions, which could lead to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1852d06432277b6ba21694a2d19f2462
https://doi.org/10.2478/jbcr-2021-0005
https://doi.org/10.2478/jbcr-2021-0005
Autor:
Doroteya K. Todorieva-Todorova, Galya Ts. Stavreva, Stefan V. Trifonov, Tihomir R. Rashev, Nikolay T. Tzvetkov, K Kovacheva, Alexander A. Todorov, P Ivanov
Publikováno v:
Journal of Biomedical and Clinical Research. 12:19-26
Summary Myeloproliferative neoplasms (MPN) are haematological diseases, characterized by clonal hematopoiesis. Hemostasis abnormalities are among the most critical and frequent complications, affecting the quality of life and a possible reason for de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4acd76d1d759d4956ab2cd0b32955629
https://doi.org/10.2478/jbcr-2019-0003
https://doi.org/10.2478/jbcr-2019-0003
Autor:
Doroteya K. Todorieva, Nikolai Tz. Tzvetkov, Vanya S. Popova, Ivailo G. Hristov, Kalina K. Ignatova, Lachezar H. Bogdanov, Pencho T. Tonchev, Dobromir D. Nguen
Summary Chronic lymphocytic leukemia is one of the most common types of leukemia affecting adults over 65 years of age [1]. The disease is a part of the so-called indolent lymphomas and has a variable clinical course, defined by many factors. In rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b003bca5cc14775196e8d7b4cce67f42
Autor:
Ralitza G. Ilieva, Petranka G. Chumpalova-Tumbeva, Vanya S. Popova, Nikolai Tz. Tzvetkov, Doroteya K. Todorieva-Todorova, Georgi K. Georgiev, Aleksandar A. Todorov, Ljudmil Z. Tumbev, Adelaida L. Ruseva, Ivailo G. Hristov, Niya A. Krasteva, Emiliya M. Dimitrova, M. Stoimenova-Popova, Valentin I. Valtchev
Publikováno v:
Journal of Biomedical and Clinical Research. 10:140-145
Summary Affective disorders, including depression, are of great social importance and lead to serious everyday life infringement and disability. Affective disorders are one of the main causes of suicide causes. Anxiety disorders represent a variety o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87260353babd30b6233364a74ed1e276
https://doi.org/10.1515/jbcr-2017-0023
https://doi.org/10.1515/jbcr-2017-0023
Autor:
Stephen T. Oh, Blanca Xicoy, Daniel El Fassi, Marianne Tang Severinsen, Tomasz Sacha, Srdan Verstovsek, Miklos Egyed, Mary Frances McMullin, Bjorn Andreasson, Doroteya K. Todorieva-Todorova, Francesco Passamonti, Ewa Lech-Marańda, Mark Kowalski, Gregg Smith, Donal P. McLornan, Claire N. Harrison, Viviane Dubruille, Christof Scheid, Ruben A. Mesa
Publikováno v:
Blood. 136:51-52
Introduction: Momelotinib (MMB) is a potent JAK1, JAK2 and ACVR1 inhibitor with clinical activity against the three hallmark features of myelofibrosis (MF), namely anemia, constitutional symptoms and splenomegaly, across the continuum of intermediate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2d0a3206d86e826fbd5bca3172537ef
https://doi.org/10.1182/blood-2020-135872
https://doi.org/10.1182/blood-2020-135872
Autor:
Andrew C. Perkins, Jeanne Palmer, Bjorn Andreasson, Srdan Verstovsek, Barbara Klencke, Tomasz Woźny, Tomasz Sacha, Mark Kowalski, Doroteya K. Todorieva-Todorova, Nathalie Cambier, Árpád Illés, Ruben A. Mesa, Francesco Passamonti, Jean-Jacques Kiladjian, Aaron T. Gerds, Christof Scheid, Claire N. Harrison, Sebastian Grosicki, David Lavie, Alessandro M. Vannucchi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S330-S331
Background: Momelotinib (MMB) is a potent, orally bioavailable, small-molecule inhibitor of JAK1, JAK2, and ACVR1 with demonstrable clinical activity against the three hallmark features of myelofibrosis (MF), namely anemia, constitutional symptoms, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::748ac685e7bbb58f8886e124d4373e84
https://doi.org/10.1016/s2152-2650(20)30993-9
https://doi.org/10.1016/s2152-2650(20)30993-9